NICE received two appeals from the consultee organisations:

  • Aegerion Pharmaceuticals Ltd
  • Lipodystrophy UK

The appeal hearing scheduled for 30 August 2019 was cancelled due to the HST committee's decision to withdraw the Final Evaluation Document (FED) following a reconsideration request from the company Aegerion Pharmaceuticals Ltd. 

This page was last updated: